ECCO IBD Curriculum

6.9. Is up to date with the evidence base from current clinical trial and real world data sets for the use of available therapies.
Exit StrategiesECCO e-Learning
Year: 2017
Authors: Johan Burisch, Ren Mao, Edyta Szymanska, Glen Doherty

This course has been developed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to provide evidence-based guidance for clinical practice so that physicians can make informed decisions in partnership with their patients regarding their optimal exit strategies.

After this course you will:

  • To recognise risks, benefits and timing of stopping anti-TNF used as monotherapy or in combination with IM in IBD.
  • To know optimal monitoring following withdrawal of biologic therapy

Crohn's disease: Perianal disease e-Coursee-Course
Year: 2020
Authors: Federica Furfaro, Kostas Katsanos, Pascal Juillerat, Pierre Ellul

This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Perianal disease in order to improve patient outcomes.

After this case you will:

  • To appreciate the Crohn’s disease natural history
  • To appreciate the rationale behind specific treatment decisions
  • To understand the right investigations to prescribe to Crohn’s disease patient in specific settings
  • To learn appropriate clinical management of Crohn’s disease patients with perianal involvement

Luminal Crohn's disease e-Coursee-Course
Year: 2020
Authors: João Sabino, Bram Verstockt, Kostas Katsanos, Pascal Juillerat, Pierre Ellul

This course has been developed by physicians who had recently participated in the writing of the ECCO Crohn's disease consensus Guidelines. This course is intended for those who are interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to Luminal disease in order to improve patient outcomes.

Upon completion of this case you will:

  • Know the evidence for induction of remission in mild-to-moderate Crohn’s disease;
  • Know the evidence for maintaining remission in  Crohn’s disease;
  • Know the evidence on how to react upon disease flares, immediately after induction therapy or during maintenance therapy; 
  • Understand the benefits and risks of several medical therapies;
  • Achieve familiarity how to use immunomodulatory agents in mono- or combination therapy;
  • Achieve familiarity how to monitor Crohn’s disease patients who initiated medical therapy or who underwent surgery;
  • Recognise indications for surgical management.

UC Update e-Coursee-Course
Year: 2016
Authors: Gianluca Pellino, Tim Raine, Dominik Bettenworth, Johan Burisch, Kristzina Gecse, Pieter Hindryck, Antonio López-Sanromán

This course is designed for gastroenterologists, surgeons, paediatricians, pathologists and other interdisciplinary medical experts interested in Inflammatory Bowel Disease(s) (IBD). One major aim of this e-learning activity is to increase competence and knowledge with regard to the prediction, diagnosis and management of Ulcerative Colitis (UC) patients and to harmonise diagnostics and treatment in order to improve patient outcomes.

Upon completion of this activity learners will:

  • Have insights into the basic epidemiology of ulcerative colitis
  • Know current treatment options for severe ulcerative colitis, including colectomy
  • Be able to use ciclosporin correctly in severe ulcerative colitis
  • Understand when to order thiopurine methyltransferase (TPMT) activity when starting azathioprine

TofacitinibEducational Audio Podcast
Year: 2020
Authors: Konstantinos Karmiris
UC Management11th N-ECCO School
Year: 2020
Authors: Mark Samaan
2nd Edition of Top Strategy TrialsTalking Heads
Year: 2019
Authors: John Mansfield, Dominik Bettenworth
VedolizumabEducational Audio Podcasts
Year: 2019
Authors: Uri Kopylov
Anti-TNF agents15th IBD Intensive Advanced Course
Year: 2017
Authors: Baert F.
Anti TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Anti-TNF agents
Files: 1
Case-based discussion: The patient with severe inflammatory Crohn’s Disease15th IBD Intensive Advanced Course
Year: 2017
Authors: Hindryckx P., Egan L.
Anti-TNF agents, Corticosteroids, Ustekinumab, Vedolizumab
Files: 1
Medical management of acute severe Ulcerative Colitis15th IBD Intensive Advanced Course
Year: 2017
Authors: Lees C.
MDT, Ileo anal pouch procedure, Laparoscopic surgery, Anti- TNF agents, Ciclosporin, Corticosteroids
Files: 1
Top Strategy TrialsTalking Heads
Year: 2017
Authors: Krisztina Gecse, Dominik Bettenworth
Transatlantic Talking Heads: Perspectives on BiosimilarsTalking Heads
Year: 2017
Authors: David Rubin, Millie Long, Silvio Danese

Talking Heads recorded by the Crohn's and Colitis Foundation in cooperation with ECCO.

Ustekinumab15th IBD Intensive Advanced Course
Year: 2017
Authors: Ferrante M.
Crohn's disease, Disease activity Indices, Ustekinumab, Colonoscopy
Files: 1
Vedolizumab15th IBD Intensive Advanced Course
Year: 2017
Authors: Lindsay J.
Therapeutic drug monitoring, Vedolizumab
Files: 1